Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab

Ocular Immunology and Inflammation

Volumn 18, Issue 3, 2010, Pages 218-222

  Khalifa, Yousuf M ^a,b   Bailony, M Rami ^b   Acharya, Nisha R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Infliximab; Pediatric; Tumor necrosis factor alpha; Uveitis; Vogt Koyanagi Harada

Indexed keywords

CYCLOPHOSPHAMIDE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIAMCINOLONE;

ADJUVANT THERAPY; ARTICLE; BLURRED VISION; CASE REPORT; CHILD; CHILD CARE; CHILDHOOD DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEADACHE; HUMAN; INTERVENTION STUDY; MAINTENANCE THERAPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; SCHOOL CHILD; SUBRETINAL FLUID; TINNITUS; UVEITIS; VOGT KOYANAGI SYNDROME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS, INTRAVENOUS; TOMOGRAPHY, OPTICAL COHERENCE; TUMOR NECROSIS FACTOR-ALPHA; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY;

EID: 77952866122     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273941003739910     Document Type: Article

References (20)

1. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46:111-122.
2. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005;20:183-190.
3. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
4. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606-614.
5. Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET Jr. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm. 1998;6:155-161.
6. Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007;27:117-123.
7. Al Hemidan AI, Tabbara KF, Althomali T. Vogt-Koyanagi- Harada associated with diabetes mellitus and celiac disease in a 3-year-old girl. Eur J Ophthalmol. 2006;16:173-177.
8. Berker N, Ozdamar Y, Soykan E, Ozdal P, Ozkan SS. Vogt-Koyanagi- Harada syndrome in children: report of a case and review of the literature. Ocul Immunol Inflamm. 2007;15:351-357.
9. Gruich MJ, Evans OB, Storey JM, Bradley ST, Chen CJ. Vogt- Koyanagi-Harada syndrome in a 4-year-old child. Pediatr Neurol. 1995;13:50-51.
10. Ikeda N, Hayasaka S, Kadoi C, Nagaki Y. Vogt-Koyanagi- Harada syndrome in an 11-year-old Boy. Ophthalmologica. 1999;213:197-199.
11. Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of pediatric Vogt-Koyanagi- Harada (VKH)- associated panuveitis. Ocul Immunol Inflamm. 2006;14:91-98.
12. Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi- Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76:723-726.
13. Rao NA. Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71-72.
14. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599-606.
15. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008;16:167-171.
16. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
17. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
18. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860-864 e2.
19. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS.. 2008;12:611-613.
20. FDA. Cancer Warnings Required for TNF-Alpha Inhibitors: U.S. Food and Drug Administration, 2009.